Drug developer Eiger Biopharmaceuticals Inc. defended its decision to file for bankruptcy in Texas, saying its sole asset in the United States is a legal retainer held in Dallas.
The company is pushing back against an April bid from the Department of Justice’s bankruptcy monitoring leg to have Eiger’s Chapter 11 case transferred or dismissed. The publicly-traded company, which filed for bankruptcy in April, develops drugs for rare metabolic diseases and listed Palo Alto, California as its principal place of business in Chapter 11 petition.
The US Trustee, which has recently been targeting what says is improper Chapter 11 venue-shopping, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.